Prostate cancer news
Read Alfred's story of joining the STAMPEDE clinical trial. His is one of the many stories featured in our 2016/17 Annual Review.
Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.
Scientists have developed a blood test that could help doctors select the best treatment for men with aggressive prostate cancer.
We take a look at results from the STAMPEDE clinical trial, which is researching how to improve treatment for men with prostate cancer.
Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.